Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05093959 · ClinicalTrials.gov registry record · Phase 2

Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction

A Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by Wake Forest University Health Sciences.

Active
Registry status
Phase 2
Development phase
86
Enrollment target
2
Study locations

NCT05093959 is a Phase 2 study of Heart Failure With Preserved Ejection Fraction that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 86 participants, below the 2,286-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05093959, a Phase 2 study of Heart Failure With Preserved Ejection Fraction, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
86 participants
Enrollment target
2
Study locations

Study Summary

Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 86 older patients with heart failure with preserved ejection fraction (HFpEF).

Conditions Studied

Heart Failure With Preserved Ejection Fraction

Interventions

  • DRUG Placebo
  • DRUG Metformin

Study Locations (2)

North Carolina

  • Atrium Health Sanger Heart and Vascular Clinic Institute - Charlotte
  • Wake Forest School of Medicine - Winston-Salem

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2022-01-04
Est. Completion 2026-04
Phase Phase 2

Sponsor

Wake Forest University Health Sciences

1,140 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05093959

The ClinicalTrials.gov registry entry for NCT05093959 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,286-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (96% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05093959 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05093959 about?

NCT05093959 is a clinical study titled "Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction". Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 86 older patients with heart failure with prese...

What is the current status of trial NCT05093959?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2022-01-04. Estimated completion is 2026-04.

What conditions does trial NCT05093959 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.

What interventions are being tested in trial NCT05093959?

The interventions under investigation include: Placebo (DRUG), Metformin (DRUG).

Who is sponsoring clinical trial NCT05093959?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05093959 being conducted?

This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Preserved Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Preserved Ejection Fraction

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.